Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 102 (2), 141-7

Use of Palmitoylethanolamide in the Entrapment Neuropathy of the Median in the Wrist

Affiliations
  • PMID: 21483401
Randomized Controlled Trial

Use of Palmitoylethanolamide in the Entrapment Neuropathy of the Median in the Wrist

R Conigliaro et al. Minerva Med.

Abstract

Aim: Carpal tunnel syndrome (CTS) is a medical condition in which the median nerve is compressed, leading to discomfort and pain. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, able to modulate inflammatory cell reactivity and pain. This study deals with the capability of PEA to normalize the electroneurographic alterations associated with moderate CTS.

Methods: Patients displaying moderate CTS were enrolled and daily PEA (600 mg or 1 200 mg/die) was administered for 30 days. Control group received no treatment.

Results: PEA treatment significantly improved the CTS-induced reduction of median nerve latency time (P<0.0004); PEA effect was dose-dependent. Tinel's sign presence and symptoms of discomfort were also reduced.

Conclusion: Although further studies are needed to better characterize PEA effect, the present report represents the first evidence on the improvement of distal motor latency elicited by PEA in patients with moderate CTS. The data support the hypothesis of protection against inflammatory and neuropathic pain by PEA.

Similar articles

See all similar articles

Cited by 13 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback